NCT04533425

Brief Summary

Syncope, or transient loss of consciousness, is a common reason for visit to the Emergency Department and often leads to extensive testing and hospitalization. Using objective risk scores to determine which patients with syncope will actually benefit from these interventions, and which can be safely discharged home with minimal testing, is critical to providing sensible medical care. This study will evaluate the validity of two syncope risk-stratification tools and investigate their impact on healthcare utilization and patient safety, thus improving the quality of care for the 1-2 million patients who experience syncope every year in the United States

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,297

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2020

Longer than P75 for all trials

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 27, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 31, 2020

Completed
14 days until next milestone

Study Start

First participant enrolled

September 14, 2020

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2024

Completed
Last Updated

April 3, 2025

Status Verified

April 1, 2025

Enrollment Period

4 years

First QC Date

August 27, 2020

Last Update Submit

April 1, 2025

Conditions

Keywords

Risk ScoreRisk StratificationExternal Validation

Outcome Measures

Primary Outcomes (2)

  • US Syncope Risk Score (The FAINT Score)

    A combination of clinical, electrocardiographic, and laboratory variables to predict the risk of serious clinical outcomes at 30 days. Full scale range from 0-6, higher score indicates higher risk of a serious cardiac event or death.

    30 days

  • Canadian Syncope Risk Score

    A combination of clinical, electrocardiographic, and laboratory variables to predict the risk of serious clinical outcomes at 30 days. Full scale range from -3 to 11, higher score indicates higher risk of a serious clinical event or death.

    30 days

Study Arms (1)

Patients with syncope

Patients who present to the ED with syncope

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adult patients who presents to the Emergency Department (ED) after an episode of syncope or pre-syncope and who do not have a new serious diagnosis found during the index ED evaluation. There are no exclusions based on sex/gender, race, or ethnicity.

You may qualify if:

  • Adult patients 40 years of age or older who present to the Emergency Department with syncope or presyncope.
  • Subjects must read and speak English or Spanish.
  • Subjects must have a working phone number and fixed address.

You may not qualify if:

  • Patient who have a syncope mimic such as seizure, stroke, head trauma with loss of consciousness, altered mental status, hypoglycemia, intoxication, or require an intervention to restore consciousness.
  • Patients who have a new serious diagnosis found in the Emergency Department, such as death, significant cardiac arrhythmia (see below), myocardial infarction, significant structural heart disease, stroke (both ischemic and hemorrhagic), pulmonary embolism, aortic dissection, hemorrhage or anemia requiring blood transfusion, subarachnoid hemorrhage, cardiopulmonary resuscitation, acute surgical illness, pregnancy, or major traumatic injury.
  • Significant cardiac arrhythmia includes Ventricular Fibrillation, Ventricular tachycardia (\>30 secs), Symptomatic ventricular tachycardia, (\<30 secs), Sick sinus disease with alternating sinus bradycardia and tachycardia, Sinus pause \> 3 seconds, Mobitz type II atrioventricular heart block, Complete heart block, Symptomatic supraventricular tachycardia (including Paroxysmal Supraventricular Tachycardia (PSVT), rapid atrial fibrillation/ flutter), Symptomatic bradycardia (pulse\<40), Pacemaker or implantable cardioverter-defibrillator malfunction with cardiac pauses.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

UC Davis

Sacramento, California, 95817, United States

Location

Icahn School of Medicine at Mount Sinai

New York, New York, 10029-6574, United States

Location

Columbia University Irving Medical Center

New York, New York, 10032, United States

Location

University of Rochester

Rochester, New York, 14642, United States

Location

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

Location

Related Publications (4)

  • Probst MA, Kanzaria HK, Gbedemah M, Richardson LD, Sun BC. National trends in resource utilization associated with ED visits for syncope. Am J Emerg Med. 2015 Aug;33(8):998-1001. doi: 10.1016/j.ajem.2015.04.030. Epub 2015 Apr 24.

    PMID: 25943042BACKGROUND
  • Probst MA, Gibson T, Weiss RE, Yagapen AN, Malveau SE, Adler DH, Bastani A, Baugh CW, Caterino JM, Clark CL, Diercks DB, Hollander JE, Nicks BA, Nishijima DK, Shah MN, Stiffler KA, Storrow AB, Wilber ST, Sun BC. Risk Stratification of Older Adults Who Present to the Emergency Department With Syncope: The FAINT Score. Ann Emerg Med. 2020 Feb;75(2):147-158. doi: 10.1016/j.annemergmed.2019.08.429. Epub 2019 Oct 23.

    PMID: 31668571BACKGROUND
  • Thiruganasambandamoorthy V, Kwong K, Wells GA, Sivilotti MLA, Mukarram M, Rowe BH, Lang E, Perry JJ, Sheldon R, Stiell IG, Taljaard M. Development of the Canadian Syncope Risk Score to predict serious adverse events after emergency department assessment of syncope. CMAJ. 2016 Sep 6;188(12):E289-E298. doi: 10.1503/cmaj.151469. Epub 2016 Jul 4.

    PMID: 27378464BACKGROUND
  • Wongtanasarasin W, Nishijima DK, Wood N, DeAngelis J, Storrow A, Schimmel J, Beltre N, Sacco D, Probst MA. Factors associated with incentive redemption among participants in a multicenter prospective syncope clinical study. Acad Emerg Med. 2024 Dec;31(12):1276-1279. doi: 10.1111/acem.14979. Epub 2024 Jun 28. No abstract available.

    PMID: 38940329BACKGROUND

Related Links

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood for cardiac biomarker testing.

MeSH Terms

Conditions

Syncope

Condition Hierarchy (Ancestors)

UnconsciousnessConsciousness DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Marc A Probst, MD, MS

    Columbia University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

August 27, 2020

First Posted

August 31, 2020

Study Start

September 14, 2020

Primary Completion

September 30, 2024

Study Completion

September 30, 2024

Last Updated

April 3, 2025

Record last verified: 2025-04

Locations